Charles Schwab Investment Management Inc. Purchases 306,430 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Charles Schwab Investment Management Inc. increased its **stake in Bristol Myers Squibb** by **0.5%**, owning approximately **60.6 million shares** valued at **$3.7 billion** as of the latest SEC filing.
• Multiple institutional investors, including **Vanguard Group** and **Ameriprise Financial**, also raised their holdings in Bristol Myers Squibb, reflecting growing **institutional interest** in the company.
• Bristol Myers Squibb reported **$12.27 billion** in revenue for the last quarter, exceeding estimates, with an **EPS of $1.46**, indicating positive financial performance despite stock price fluctuations.

Charles Schwab Investment Management Inc. raised its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.5% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 60,606,905 shares of the biopharmaceutical company's stock after purchasing an additional 306,430 shares during the period. Charles Schwab Investment Management Inc. owned 2.98% of Bristol Myers Squibb worth $3,696,415,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. ASR Vermogensbeheer N.V. purchased a new position in shares of Bristol Myers Squibb in the first quarter valued at about $14,413,000. Citizens Financial Group Inc. RI lifted its position in shares of Bristol Myers Squibb by 18.0% in the first quarter. Citizens Financial Group Inc. RI now owns 35,337 shares of the biopharmaceutical company's stock valued at $2,155,000 after acquiring an additional 5,395 shares in the last quarter. Greykasell Wealth Strategies Inc. purchased a new position in shares of Bristol Myers Squibb in the first quarter valued at about $117,000. Primecap Management Co. CA lifted its position in shares of Bristol Myers Squibb by 0.9% in the first quarter. Primecap Management Co. CA now owns 22,970,633 shares of the biopharmaceutical company's stock valued at $1,400,979,000 after acquiring an additional 197,453 shares in the last quarter. Finally, Fi3 FINANCIAL ADVISORS LLC lifted its position in shares of Bristol Myers Squibb by 9.3% in the first quarter. Fi3 FINANCIAL ADVISORS LLC now owns 3,885 shares of the biopharmaceutical company's stock valued at $237,000 after acquiring an additional 330 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

BMY has been the topic of several research analyst reports. Jefferies Financial Group lowered their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Citigroup decreased their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $56.38.

Bristol Myers Squibb Trading Up 0.0%

NYSE BMY traded up $0.01 during trading hours on Monday, hitting $45.96. 2,167,301 shares of the company were exchanged, compared to its average volume of 13,424,913. The stock has a 50-day moving average price of $47.32 and a 200 day moving average price of $51.82. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33. The stock has a market cap of $93.55 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 2.35 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 earnings per share. Analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.